drugset / Trial / NCT00511849

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

NCT00511849

Phase 1 Completed 43 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.

Timeline

Start
2005-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown
Subject Paclitaxel Small molecule 175 mg/m2
Subject Paclitaxel Small molecule 200 mg/m2
Subject Paclitaxel Small molecule 225 mg/m2
Subject Sunitinib Small molecule 25 mg Oral
Subject Sunitinib Small molecule 37.5 mg Oral
Subject Sunitinib Small molecule 50 mg Oral

Indications